One common way is through sequencing of a patient’s cancer cells to identify cancer-specific mutations that can be targeted, which are processed through an MHC-binding prediction to enrich the antigens for those that are more likely to be presented to T-cells [40], test these using HLA-tetramers [41], finally identifying TCRs that target these antigens through clonal T-cell analyses or single cell sequencing [42,43,44]. The gene discussed is HLA-C; the disease is cancer.